8 / 8
allied
academies
CANCER STEM CELLS AND
ONCOLOGY RESEARCH
11
th
International Conference on
J u n e 1 1 - 1 3 , 2 0 1 8 | D u b l i n , I r e l a n d
Journal of Medical Oncology and Therapeutics
|
Volume 3
Page 36
P
rostate cancer (CaP) is the most common cancer in males in
Australia which caused more than 3000 deaths in 2015. EpCAM is
a transmembrane protein that is expressed at low levels in a variety
of human epithelial tissues, but overexpressed in most solid tumors.
Our previous study indicated that EpCAM was strongly expressed in
metastatic CaP cell lines, primary human CaP tissues and lymph node
metastasis and is a biomarker involved inCaPprogression, and chemo-/
radio-resistance. However, the role of EpCAM in CaP progression and
therapeutic resistance is still uncertain. The aim of this study was to
investigate the role of EpCAM in CaP progression and chemo-/radio-
resistance as well as underlying mechanisms using
in vitro
CaP cell
lines and
in vivo
mouse models for a potential therapeutic target.
Biography
Yong Li obtained his PhD degree at University of
New South Wales (UNSW), Australia in 2000. He
became Cancer Research Group leader in 2006,
and is an established cancer researcher, with ex-
pertise in cancer biomarker discovery, radiation
biology, target cancer therapy and cancer metas-
tasis. Currently, he is Principal Scientific Officer
and Head of Cancer Research Programat Cancer
Care Centre, St George Hospital, and Associate
Professor at St George and Sutherland Clinical
School, UNSW Australia. He has published more
than 100 papers and book chapters in peer-re-
viewed journals in cancer research area. His cur-
rent research program is aimed at: To investigate
novel biomarkers from human body fluids and
tissues, cancer cell lines and animal models for
cancer diagnosis and developing personalized
medicine; to investigate mechanisms of cancer
metastasis and chemo-/radio-resistance and role
of tumor microenvironment, cancer stem cells
and epithelial-mesenchymal transition in cancer
progression; to use targeted cancer therapy and
combination therapy to control metastatic and
therapeutic resistant cancers.
y.li@unsw.edu.auEPITHELIAL CELL ADHESION
MOLECULE (EpCAM) AS A CSC
MARKER IN PROSTATE CANCER
CHEMO-/RADIO-RESISTANCE
Yong Li
1
St George Hospital, Australia
2
University of New South Wales, Australia
Yong Li, J Med Oncl Ther 2018, Volume 3